All In Biotech

Drug Trial Radar · NCT00163449

Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)

BALLOON: Efficacy and Safety - Study by ALTANA on Ciclesonide in Pre-school Asthma Patients

Last checked: Nov 19, 2026Latest source record: Dec 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Planned (sponsor's estimate)

Start

Nov 2005

Primary completion

Nov 2006

Study completion May 2007

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 14, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Who can join
All sexes, from 2 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the present study is to compare the efficacy of inhaled ciclesonide in pre-school children. Ciclesonide will be inhaled once daily, using one of three dose levels and tested versus placebo. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety and tolerability of ciclesonide.

Conditions

  • Asthma

Interventions

  • CiclesonideDrug

    Efficacy and Safety of Ciclesonide

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. time to first moderate or severe asthma exacerbation.Time frame: 24 weeks

Locations

96 sites in 9 countries. Site status is shown where the registry gives one.

  • Altana Pharma/Nycomed

    Campinas - SP, Brazil

  • Altana Pharma/Nycomed

    Curitiba-PR, Brazil

  • Altana Pharma/Nycomed

    Paraná, Brazil

  • Altana Pharma/Nycomed

    Pinheiros Sao Paulo - SP, Brazil

  • Altana Pharma/Nycomed

    Porto Alegre-RS, Brazil

  • Altana Pharma/Nycomed

    Porto Alegre-RS, Brazil

  • Altana Pharma/Nycomed

    Recife-PE, Brazil

  • Altana Pharma/Nycomed

    Rio de Janeiro-RJ, Brazil

  • Altana Pharma/Nycomed

    Rio Grande, Brazil

  • Altana Pharma/Nycomed

    Salvador - Bahia, Brazil

  • Altana Pharma/Nycomed

    Santo André-SP, Brazil

  • Altana Pharma/Nycomed

    São Paulo, Brazil

  • Altana Pharma/Nycomed

    São Paulo, Brazil

  • Altana Pharma/Nycomed

    São Paulo, Brazil

  • Altana Pharma/Nycomed

    São Paulo, Brazil

  • Altana Pharma/Nycomed

    Sao Paulo - SP, Brazil

  • Altana Pharma/Nycomed

    Sao Paulo-SP, Brazil

  • Altana Pharma/Nycomed

    São Paulo-SP, Brazil

  • Altana Pharma/Nycomed

    Berlin, Germany

  • Altana Pharma/Nycomed

    Cologne, Germany

  • Altana Pharma/Nycomed

    Dresden, Germany

  • Altana Pharma/Nycomed

    Düsseldorf, Germany

  • Altana Pharma/Nycomed

    Frankfurt, Germany

  • Altana Pharma/Nycomed

    Heidelberg, Germany

  • Altana Pharma/Nycomed

    Mannheim, Germany

  • Altana Pharma/Nycomed

    München, Germany

  • Altana Pharma/Nycomed

    Rosenheim, Germany

  • Altana Pharma/Nycomed

    Wesel, Germany

  • Altana Pharma/Nycomed

    Wiefelstede, Germany

  • Altana Pharma/Nycomed

    Baja, Hungary

  • Altana Pharma/Nycomed

    Budapest, Hungary

  • Altana Pharma/Nycomed

    Budapest, Hungary

  • Altana Pharma/Nycomed

    Budapest, Hungary

  • Altana Pharma/Nycomed

    Debrecen, Hungary

  • Altana Pharma/Nycomed

    Jászberény, Hungary

  • Altana Pharma/Nycomed

    Kaposvár, Hungary

  • Altana Pharma/Nycomed

    Kiskunhalas, Hungary

  • Altana Pharma/Nycomed

    Miskolc, Hungary

  • Altana Pharma/Nycomed

    Mosdós, Hungary

  • Altana Pharma/Nycomed

    Mosonmagyaróvár, Hungary

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.